S11-6 "6. Closing and Summary"(SYMPOSIUM 11: REGULATORY SCIENCE IN TOXICOLOGY RESEARCH : INTERPRETATION OF DEFINITION AND SIGNIFICANCE OF NOAEL (NON-OBSERVED ADVERSE EFFECT LEVEL) FOR PHARMACEUTICALS)(Proceedings of the 31st Annual Meeting)
スポンサーリンク
概要
- 論文の詳細を見る
- 日本トキシコロジー学会の論文
- 2004-10-29
著者
関連論文
- Safety assessment of biopharmaceuticals : Japanese perspective on ICH S6 guideline maintenance
- CURRENT OPINION : SAFETY EVALUATION OF DRUG METABOLITES IN DEVELOPMENT OF PHARMACEUTICALS
- "POINTS TO CONSIDER" REGARDING SAFETY ASSESSMENT OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS IN NON-CLINICAL STUDIES (ENGLISH TRANSLATION)
- Review of an alternative to animal testing for safety evaluation of Quasi-drug
- Preclinical safety studies of anticancer agents : Cytotoxic agents(Breaking Through the Stage of Non-clinical to Clinical in the Drug Development Process, Proceedings of the 32nd Annual Meeting)
- S11-6 "6. Closing and Summary"(SYMPOSIUM 11: REGULATORY SCIENCE IN TOXICOLOGY RESEARCH : INTERPRETATION OF DEFINITION AND SIGNIFICANCE OF NOAEL (NON-OBSERVED ADVERSE EFFECT LEVEL) FOR PHARMACEUTICALS)(Proceedings of the 31st Annual Meeting)
- S11-1 Toxicology on Regulatory Sciences ; Interpretation of Definition and Signiflcance of NOAEL (No Observed Adverse Effect Level) for Pharmaceuticals(SYMPOSIUM 11: REGULATORY SCIENCE IN TOXICOLOGY RESEARCH : INTERPRETATION OF DEFINITION AND SIGNIFICANCE
- Perspectives on non-clinical safety evaluation of drug metabolites through the JSOT workshop